| 2.59 0.02 (0.78%) | 04-29 14:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4 | 1-year : | 4.85 |
| Resists | First : | 3.42 | Second : | 4.15 |
| Pivot price | 2.73  |
|||
| Supports | First : | 2.25 | Second : | 1.87 |
| MAs | MA(5) : | 2.46 |
MA(20) : | 2.82 |
| MA(100) : | 2.9 |
MA(250) : | 2.71 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.4 |
D(3) : | 3.8 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 5.09 | Low : | 1.63 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BRNS ] has closed above bottom band by 21.5%. Bollinger Bands are 64.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.6 - 2.62 | 2.62 - 2.63 |
| Low: | 2.37 - 2.38 | 2.38 - 2.4 |
| Close: | 2.47 - 2.5 | 2.5 - 2.52 |
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Sat, 27 Apr 2024
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Up 39.6% in April - MarketBeat
Fri, 19 Apr 2024
Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives - Markets Insider
Fri, 19 Apr 2024
Barinthus Biotherapeutics (NASDAQ:BRNS) Given "Buy" Rating at HC Wainwright - MarketBeat
Thu, 18 Apr 2024
Barinthus Bio reports mixed results in APOLLO trial - Investing.com
Thu, 18 Apr 2024
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human ... - GlobeNewswire
Fri, 05 Apr 2024
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 1.837e+007 (%) |
| Held by Institutions | 3.6 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.817e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 24.6 % |
| Return on Equity (ttm) | -20.8 % |
| Qtrly Rev. Growth | 802000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 10130 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|